Expert Q&A Archives - AzurBio - Accelerating biopharmas expansion to EU

Expert Q&A

What is the “Exploitant” status and why is it essential for pharmaceutical companies entering the French Market?

What is the “Exploitant” status and why is it essential for pharmaceutical companies entering the French Market? What's Inside the Q&A: Access Senior-Level Know-How Learn from experts who have shaped…

Expert Q&A

Should we launch ourselves in Europe or consider partnering/outlicensing, and how do we decide?

Explore how biopharma leaders weigh launching independently versus partnering in Europe, and how to decide.

Expert Q&A

Launching in EU – Q&A 8

What risk areas should we pay special attention to (pharmacovigilance, legal, compliance, etc.) when launching in Europe?

Expert Q&A

What are the key operational flows we need to set up for product distribution in Europe?

What are the key operational flows we need to set up for product distribution in Europe? What's Inside the Q&A: Quality Oversight Frameworks Discover how Europe’s unique release and certification…

Expert Q&A

What are Early Access Programs (EAPs) in Europe, and how can they help gather real-world data?

Expert Q&A

First interactions with EMA – Q&A 6

What CMC (Chemistry, Manufacturing, and Controls) expectations in the EU might surprise biopharma companies?

Expert Q&A

First interactions with EMA – Q&A 5

Get expert insights on your first interactions with the European Medicines Agency. Learn how to choose the right regulatory pathway, compare timelines, and navigate EU procedures with confidence.

Expert Q&A

What is a Pediatric Investigation Plan (PIP) and when should we plan for it in Europe?

Expert Q&A

How do we ensure compliance with local promotional regulations and get our marketing materials approved in Europe?

Expert Q&A

How should we plan our launch sequencing across European countries, considering timelines for approval, pricing, and access?

Resources

What is the “Exploitant” status and why is it essential for pharmaceutical companies entering the French Market?

Should we launch ourselves in Europe or consider partnering/outlicensing, and how do we decide?

Launching in EU – Q&A 8

What are the key operational flows we need to set up for product distribution in Europe?

What are Early Access Programs (EAPs) in Europe, and how can they help gather real-world data?

First interactions with EMA – Q&A 6

First interactions with EMA – Q&A 5

What is a Pediatric Investigation Plan (PIP) and when should we plan for it in Europe?

How do we ensure compliance with local promotional regulations and get our marketing materials approved in Europe?

How should we plan our launch sequencing across European countries, considering timelines for approval, pricing, and access?

Looking to enter the EU market?
Contact us today.

Resources

What is the “Exploitant” status and why is it essential for pharmaceutical companies entering the French Market?

Should we launch ourselves in Europe or consider partnering/outlicensing, and how do we decide?

Launching in EU – Q&A 8

What are the key operational flows we need to set up for product distribution in Europe?

What are Early Access Programs (EAPs) in Europe, and how can they help gather real-world data?

First interactions with EMA – Q&A 6

First interactions with EMA – Q&A 5

What is a Pediatric Investigation Plan (PIP) and when should we plan for it in Europe?

How do we ensure compliance with local promotional regulations and get our marketing materials approved in Europe?

How should we plan our launch sequencing across European countries, considering timelines for approval, pricing, and access?

Looking to enter the EU market? Contact us today.

Looking to enter the EU market?
Contact us today.